Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Xilio Therapeutics, Inc. - Common Stock (NQ:XLO)

0.5101 -0.0012 (-0.23%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Xilio Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Why Aclarion Shares Are Trading Higher By Around 53%; Here Are 20 Stocks Moving Premarket ↗
Shares of Aclarion, Inc. (NASDAQ: ACON) shares rose sharply in pre-market trading after the company was granted U.S. patent #11844601 for "MR SPECTROSCOPY SYSTEM FOR DIAGNOSING PAINFUL AND NON-PAINFUL... 
Via Benzinga
Topics Intellectual Property
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy Data
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial Results
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, in Late Line Patients with Advanced Solid Tumors
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio to Host Virtual Investor Conference Call and Webcast on Monday, November 6, 2023 to Review Progress Across Pipeline, Including Phase 1/2 Clinical Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, Presented at the SITC Annual Meeting
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Xilio Therapeutics Announces Promotion of Katarina Luptakova, M.D., to Chief Medical Officer and Scott Coleman, Ph.D., to Chief Development Officer
Martin Huber, M.D., to leave Xilio Therapeutics and remain an advisor 
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2023 Financial Results
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics Announces Promotion of Chris Frankenfield to Chief Operating Officer
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics Announces Preliminary Clinical Data from Phase 1 Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Patients with Advanced Solid Tumors
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2023 Financial Results
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics Announces Pipeline and Business Updates for the Fourth Quarter and Full Year 2022 Financial Results
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics to Present at Upcoming Investor Conferences
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics to Present at the Citi 2023 Virtual Oncology Leadership Summit
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Xilio Therapeutics to Present at the Guggenheim Healthcare Talks Oncology Day
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Why Panbela Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Gainers MicroAlgo Inc. (NASDAQ: MLGO) shares jumped 74% to $2.90. MicroAlgo recently entered into securities purchase agreement for up to $3.2 million. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
  On Wednesday, 152 stocks made new 52-week lows. 
Via Benzinga
News headline image
Why Grom Social Enterprises Shares Are Trading Lower By 30%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) shares surged 85% to $2.2200. Sonoma Pharmaceuticals and EMC Pharma announced Department of Defense DAPA registration for Microcyn(R) Rx products. 
Via Benzinga
News headline image
Why PagSeguro Digital Shares Are Trading Lower By 18%? Here Are 40 Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers Cosmos Holdings Inc. (NASDAQ: COSM) rose 68% to $0.5500 after surging around 87% on Tuesday. Cosmos Holdings recently posted a Q3 loss of $0.08 per share. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For December 21, 2022 ↗
 
Via Benzinga
News headline image
Xilio Therapeutics to Host Live Virtual Program Spotlighting XTX301, a Tumor-Activated IL-12
From Xilio Therapeutics, Inc.
Via GlobeNewswire
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
  On Tuesday, 298 companies achieved new lows for the year. 
Via Benzinga
News headline image
Why Coupa Software Shares Jumped Around 29%; Here Are 72 Biggest Movers From Wednesday ↗
Gainers Kalera Public Limited Company (NASDAQ: KAL) jumped 76.9% to close at $0.1610 on Wednesday after gaining 9% on Tuesday. Kalera recently posted a Q3 loss of $0.05 per share. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.